Melanoma. Part I. Risk Assessment, Diagnosis, and Prognosis: Using Molecular Tools to Diagnose Melanoma, Predict Its Behavior, and Evaluate for Inheritable Forms

2014 ◽  
pp. 63-96 ◽  
Author(s):  
Gregory A. Hosler ◽  
Kathleen M. Murphy
Keyword(s):  
Risk Assessment ◽  
Molecular Tools ◽  
Diagnosis And Prognosis

Hypercoagulation screening as an innovative tool for risk assessment, early diagnosis and prognosis in cancer: the HYPERCAN study

2016 ◽  
Vol 140 ◽  
pp. S55-S59 ◽  
Author(s):  
Anna Falanga ◽  
Armando Santoro ◽  
Roberto Labianca ◽  
Filippo De Braud ◽  
Giampietro Gasparini ◽  
...  
Keyword(s):  
Risk Assessment ◽  
Early Diagnosis ◽  
Diagnosis And Prognosis ◽  
Innovative Tool

Prostatic Specific Antigen Less then 10 ng/mL in the Diagnostic and Surveillance of Prostate Cancer

2017 ◽  
Vol 68 (5) ◽  
pp. 933-936
Author(s):  
Nicolae Grigore ◽  
Valentin Pirvut ◽  
Ionela Mihai ◽  
Adrian Hasegan ◽  
Sebastian Ioan Cernusca Mitariu
Keyword(s):  
Prostate Cancer ◽  
Risk Assessment ◽  
Early Diagnosis ◽  
Clinical Management ◽  
Specific Antigen ◽  
Prostatic Specific Antigen ◽  
Inclusion Criteria ◽  
Diagnosis And Prognosis ◽  
Therapeutic Decisions ◽  
Risk Scale

Prostate cancer (PCa) is the most commonly diagnosed male malignancy after 60 years old. Today, the problem is to distinguish between low-risk and agrressive cancers, especially in patients with Prostatic Specific Antigen (PSA) less than 10 ng/ml The use of PSA as a biomarkers for diagnosis and prognosis of prostate cancer has the potential to improve the clinical management of the patients. PSA levels. together with clinical examination, prostate ultrasound and histopatological examination are esential for the diagnostic of PCa, risk assessment and therapeutic decisions. The aim of our study is to evaluate the patients with PSA values less then 10 ng/mL and to determine the correct indications for tratment depending on the risk scale of the disease. The inclusion criteria for the patients are described in the paper. For improving the early diagnosis of PCa in patients with PSA below 10 ng/mL we developed an algoritm based on current opportunities.

Morphologic differences between abdominal and inguinal testes in stallions

1987 ◽  
Vol 45 ◽  
pp. 820-821
Author(s):  
F. Al-Bagdadi ◽  
D. Hoyt ◽  
P. Karns ◽  
G. Martin ◽  
M. Memon ◽  
...  
Keyword(s):  
Carcinoma Cells ◽  
Genital System ◽  
Diagnosis And Prognosis ◽  
Male Genital System ◽  
Morphological Differences ◽  
Hormone Imbalance ◽  
Made In ◽  
Male Genital

The most frequently occuring abnormality of the male genital system in mammals is the failure of one or both testes to descend into the scrotum. The reasons for abdominal or inguinal retention of testes could be anatomic malformation, faulty development or hormone imbalance.Cryptorchidism has been associated with either greatly reduced or absent spermatogenesis (Kaueakami et al, 1984), and being a source of neoplasia. According to Stick (1980), germinal carcinoma cells have been believed to be the cause of teratomas in equine cryptorchid testicles. Neoplasia has been reported in descended testes of unilateral cryptorchid patients (Martin et al, 1981).No distinction has been made in relating the problem of cryptorchid testes to inguinal or abdominal retention. The purpose of this study is to record the morphological differences between inguinal and abdominal cryptorchid testes as an aid in diagnosis and prognosis.

Risk assessment in dentistry

1998 ◽  
Vol 62 (10) ◽  
pp. 756-761 ◽  
Author(s):  
CW Douglass
Keyword(s):  
Risk Assessment

The miR-21 potential of serving as a biomarker for liver diseases in clinical practice

2020 ◽  
Vol 48 (5) ◽  
pp. 2295-2305
Author(s):  
Jiawei Zhang ◽  
Dandan Li ◽  
Rui Zhang ◽  
Peng Gao ◽  
Rongxue Peng ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Liver Diseases ◽  
Hepatic Disease ◽  
Noninvasive Detection ◽  
Diagnosis And Prognosis ◽  
Expected Performance ◽  
Potential Biomarker ◽  
Disease Condition ◽  
Complex Regulatory Network

The role of miR-21 in the pathogenesis of various liver diseases, together with the possibility of detecting microRNA in the circulation, makes miR-21 a potential biomarker for noninvasive detection. In this review, we summarize the potential utility of extracellular miR-21 in the clinical management of hepatic disease patients and compared it with the current clinical practice. MiR-21 shows screening and prognostic value for liver cancer. In liver cirrhosis, miR-21 may serve as a biomarker for the differentiating diagnosis and prognosis. MiR-21 is also a potential biomarker for the severity of hepatitis. We elucidate the disease condition under which miR-21 testing can reach the expected performance. Though miR-21 is a key regulator of liver diseases, microRNAs coordinate with each other in the complex regulatory network. As a result, the performance of miR-21 is better when combined with other microRNAs or classical biomarkers under certain clinical circumstances.

Sign in / Sign up

Export Citation Format

Share Document